{
  "DOI": "10.1007/s10689-021-00227-3",
  "ISSN": [
    "1389-9600",
    "1573-7292"
  ],
  "URL": "http://dx.doi.org/10.1007/s10689-021-00227-3",
  "abstract": "\u003cjats:title\u003eAbstract\u003c/jats:title\u003e\u003cjats:p\u003eImprovements in DNA sequencing technology and discoveries made by large scale genome-wide association studies have led to enormous insight into the role of genetic variation in prostate cancer risk. High-risk prostate cancer risk predisposition genes exist in addition to common germline variants conferring low-moderate risk, which together account for over a third of familial prostate cancer risk. Identifying men with additional risk factors such as genetic variants or a positive family history is of clinical importance, as men with such risk factors have a higher incidence of prostate cancer with some evidence to suggest diagnosis at a younger age and poorer outcomes. The medical community remains in disagreement on the benefits of a population prostate cancer screening programme reliant on PSA testing. A reduction in mortality has been demonstrated in many studies, but at the cost of significant amounts of overdiagnosis and overtreatment. Developing targeted screening strategies for high-risk men is currently the subject of investigation in a number of prospective studies. At present, approximately 38% of the familial risk of PrCa can be explained based on published SNPs, with men in the top 1% of the risk profile having a 5.71-fold increase in risk of developing cancer compared with controls. With approximately 170 prostate cancer susceptibility loci now identified in European populations, there is scope to explore the clinical utility of genetic testing and genetic-risk scores in prostate cancer screening and risk stratification, with such data in non-European populations eagerly awaited. This review will focus on both the rare and common germline genetic variation involved in hereditary and familial prostate cancer, and discuss ongoing research in exploring the role of targeted screening in this high-risk group of men.\u003c/jats:p\u003e",
  "alternative-id": [
    "227"
  ],
  "assertion": [
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Received",
      "name": "received",
      "order": 1,
      "value": "29 September 2020"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Accepted",
      "name": "accepted",
      "order": 2,
      "value": "4 January 2021"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "First Online",
      "name": "first_online",
      "order": 3,
      "value": "24 January 2021"
    },
    {
      "group": {
        "label": "Compliance with ethical standards",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 1
    },
    {
      "group": {
        "label": "Conflict of interest",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 2,
      "value": "GU-ASCO meeting in San Francisco—Jan 2016—Honorarium as speaker $500. RMH FR meeting—Nov 2017—support from Janssen, honorarium as speaker £1100 (Title: Genetics and Prostate Cancer). University of Chicago invited talk May 2018—Honorarium as speaker $1000. EUR 200 educational honorarium paid by Bayer \u0026 Ipsen to attend GU Connect “Treatment sequencing for mCRPC patients within the changing landscape of mHSPC” at a venue at ESMO, Barcelona, 28 September 2019. Prostate Dx Advisory Panel—Member of external Expert Committee. 30th June 2020/3 h/£900. Rosalind Eeles is Chief Investigator of the PROFILE, IMACT and BARCODE1 studies."
    }
  ],
  "author": [
    {
      "ORCID": "http://orcid.org/0000-0003-0268-4138",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Ni Raghallaigh",
      "given": "Holly",
      "sequence": "first"
    },
    {
      "affiliation": [],
      "family": "Eeles",
      "given": "Rosalind",
      "sequence": "additional"
    }
  ],
  "container-title": [
    "Familial Cancer"
  ],
  "content-domain": {
    "crossmark-restriction": false,
    "domain": [
      "link.springer.com"
    ]
  },
  "created": {
    "date-parts": [
      [
        2021,
        1,
        24
      ]
    ],
    "date-time": "2021-01-24T02:03:35Z",
    "timestamp": 1611453815000
  },
  "deposited": {
    "date-parts": [
      [
        2022,
        12,
        13
      ]
    ],
    "date-time": "2022-12-13T02:18:23Z",
    "timestamp": 1670897903000
  },
  "indexed": {
    "date-parts": [
      [
        2024,
        4,
        28
      ]
    ],
    "date-time": "2024-04-28T09:53:31Z",
    "timestamp": 1714298011457
  },
  "is-referenced-by-count": 19,
  "issn-type": [
    {
      "type": "print",
      "value": "1389-9600"
    },
    {
      "type": "electronic",
      "value": "1573-7292"
    }
  ],
  "issue": "1",
  "issued": {
    "date-parts": [
      [
        2021,
        1,
        24
      ]
    ]
  },
  "journal-issue": {
    "issue": "1",
    "published-print": {
      "date-parts": [
        [
          2022,
          1
        ]
      ]
    }
  },
  "language": "en",
  "license": [
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "tdm",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2021,
            1,
            24
          ]
        ],
        "date-time": "2021-01-24T00:00:00Z",
        "timestamp": 1611446400000
      }
    },
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "vor",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2021,
            1,
            24
          ]
        ],
        "date-time": "2021-01-24T00:00:00Z",
        "timestamp": 1611446400000
      }
    }
  ],
  "link": [
    {
      "URL": "https://link.springer.com/content/pdf/10.1007/s10689-021-00227-3.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://link.springer.com/article/10.1007/s10689-021-00227-3/fulltext.html",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://link.springer.com/content/pdf/10.1007/s10689-021-00227-3.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "member": "297",
  "page": "101-114",
  "prefix": "10.1007",
  "published": {
    "date-parts": [
      [
        2021,
        1,
        24
      ]
    ]
  },
  "published-online": {
    "date-parts": [
      [
        2021,
        1,
        24
      ]
    ]
  },
  "published-print": {
    "date-parts": [
      [
        2022,
        1
      ]
    ]
  },
  "publisher": "Springer Science and Business Media LLC",
  "reference": [
    {
      "author": "O Bratt",
      "first-page": "588",
      "journal-title": "BJU Int",
      "key": "227_CR1",
      "unstructured": "Bratt O (2000) Hereditary prostate cancer. BJU Int 855:588–598",
      "volume": "855",
      "year": "2000"
    },
    {
      "DOI": "10.1038/s41588-018-0142-8",
      "author": "FR Schumacher",
      "doi-asserted-by": "crossref",
      "first-page": "928",
      "journal-title": "Nat Genet",
      "key": "227_CR2",
      "unstructured": "Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T et al (2018) Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet 507:928–936",
      "volume": "507",
      "year": "2018"
    },
    {
      "DOI": "10.1158/1055-9965.EPI-16-1046",
      "author": "S Benafif",
      "doi-asserted-by": "crossref",
      "first-page": "845",
      "journal-title": "Cancer Epidemiol Biomark Prev",
      "key": "227_CR3",
      "unstructured": "Benafif S, Kote-Jarai Z, Eeles RA, Consortium P (2018) A review of prostate cancer genome-wide association studies (GWAS). Cancer Epidemiol Biomark Prev 278:845–857",
      "volume": "278",
      "year": "2018"
    },
    {
      "DOI": "10.1038/nature08494",
      "author": "TA Manolio",
      "doi-asserted-by": "crossref",
      "first-page": "747",
      "journal-title": "Nature",
      "key": "227_CR4",
      "unstructured": "Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, McCarthy MI et al (2009) Finding the missing heritability of complex diseases. Nature 4617265:747–753",
      "volume": "4617265",
      "year": "2009"
    },
    {
      "DOI": "10.1016/S0022-5347(17)35617-3",
      "author": "BS Carter",
      "doi-asserted-by": "crossref",
      "first-page": "797",
      "journal-title": "J Urol",
      "key": "227_CR5",
      "unstructured": "Carter BS, Bova GS, Beaty TH, Steinberg GD, Childs B, Isaacs WB, Walsh PC (1993) Hereditary prostate cancer: epidemiologic and clinical features. J Urol 1503:797–802",
      "volume": "1503",
      "year": "1993"
    },
    {
      "DOI": "10.1097/00005392-199606000-00004",
      "author": "DW Keetch",
      "doi-asserted-by": "crossref",
      "first-page": "1841",
      "journal-title": "J Urol",
      "key": "227_CR6",
      "unstructured": "Keetch DW, Humphrey PA, Smith DS, Stahl D, Catalona WJ (1996) Clinical and pathological features of hereditary prostate cancer. J Urol 1556:1841–1843",
      "volume": "1556",
      "year": "1996"
    },
    {
      "DOI": "10.1016/S0959-8049(98)00358-X",
      "author": "O Bratt",
      "doi-asserted-by": "crossref",
      "first-page": "272",
      "journal-title": "Eur J Cancer",
      "key": "227_CR7",
      "unstructured": "Bratt O, Kristoffersson U, Lundgren R, Olsson H (1999) Familial and hereditary prostate cancer in southern Sweden. A population-based case-control study. Eur J Cancer 352:272–277",
      "volume": "352",
      "year": "1999"
    },
    {
      "DOI": "10.1093/jnci/86.21.1600",
      "author": "DE Goldgar",
      "doi-asserted-by": "crossref",
      "first-page": "1600",
      "journal-title": "J Natl Cancer Inst",
      "key": "227_CR8",
      "unstructured": "Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH (1994) Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 8621:1600–1608",
      "volume": "8621",
      "year": "1994"
    },
    {
      "DOI": "10.1038/sj.pcan.4500257",
      "author": "EA Klein",
      "doi-asserted-by": "crossref",
      "first-page": "297",
      "journal-title": "Prostate Cancer Prostatic Dis",
      "key": "227_CR9",
      "unstructured": "Klein EA, Kupelian PA, Witte JS (1998) Does a family history of prostate cancer result in more aggressive disease? Prostate Cancer Prostatic Dis 16:297–300",
      "volume": "16",
      "year": "1998"
    },
    {
      "DOI": "10.1056/NEJM200007133430201",
      "author": "P Lichtenstein",
      "doi-asserted-by": "crossref",
      "first-page": "78",
      "journal-title": "N Engl J Med",
      "key": "227_CR10",
      "unstructured": "Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E et al (2000) Environmental and heritable factors in the causation of cancer–analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 3432:78–85",
      "volume": "3432",
      "year": "2000"
    },
    {
      "DOI": "10.1158/1055-9965.EPI-13-0568",
      "author": "JB Hjelmborg",
      "doi-asserted-by": "crossref",
      "first-page": "2303",
      "journal-title": "Cancer Epidemiol Biomark Prev",
      "key": "227_CR11",
      "unstructured": "Hjelmborg JB, Scheike T, Holst K, Skytthe A, Penney KL, Graff RE, Pukkala E et al (2014) The heritability of prostate cancer in the Nordic twin study of cancer. Cancer Epidemiol Biomark Prev 2311:2303–2310",
      "volume": "2311",
      "year": "2014"
    },
    {
      "DOI": "10.1002/1097-0215(200102)9999:9999\u003c::AID-IJC1147\u003e3.0.CO;2-C",
      "author": "C Dong",
      "doi-asserted-by": "crossref",
      "first-page": "144",
      "journal-title": "Int J Cancer",
      "key": "227_CR12",
      "unstructured": "Dong C, Hemminki K (2001) Modification of cancer risks in offspring by sibling and parental cancers from 2,112,616 nuclear families. Int J Cancer 921:144–150",
      "volume": "921",
      "year": "2001"
    },
    {
      "DOI": "10.1016/S0022-5347(17)36733-2",
      "author": "WP McWhorter",
      "doi-asserted-by": "crossref",
      "first-page": "826",
      "journal-title": "J Urol",
      "key": "227_CR13",
      "unstructured": "McWhorter WP, Hernandez AD, Meikle AW, Terreros DA, Smith JA Jr, Skolnick MH, Cannon-Albright LA et al (1992) A screening study of prostate cancer in high risk families. J Urol 1483:826–828",
      "volume": "1483",
      "year": "1992"
    },
    {
      "DOI": "10.1200/JCO.1997.15.4.1478",
      "author": "PA Kupelian",
      "doi-asserted-by": "crossref",
      "first-page": "1478",
      "journal-title": "J Clin Oncol",
      "key": "227_CR14",
      "unstructured": "Kupelian PA, Kupelian VA, Witte JS, Macklis R, Klein EA (1997) Family history of prostate cancer in patients with localized prostate cancer: an independent predictor of treatment outcome. J Clin Oncol 154:1478–1480",
      "volume": "154",
      "year": "1997"
    },
    {
      "DOI": "10.1016/S0022-5347(01)68194-1",
      "author": "PA Kupelian",
      "doi-asserted-by": "crossref",
      "first-page": "2197",
      "journal-title": "J Urol",
      "key": "227_CR15",
      "unstructured": "Kupelian PA, Klein EA, Witte JS, Kupelian VA, Suh JH (1997) Familial prostate cancer: a different disease? J Urol 1586:2197–2201",
      "volume": "1586",
      "year": "1997"
    },
    {
      "author": "GS Bova",
      "first-page": "660",
      "issue": "Pt 1",
      "journal-title": "J Urol",
      "key": "227_CR16",
      "unstructured": "Bova GS, Partin AW, Isaacs SD, Carter BS, Beaty TL, Isaacs WB, Walsh PC (1998) Biological aggressiveness of hereditary prostate cancer: long-term evaluation following radical prostatectomy. J Urol 1603(Pt 1):660–663",
      "volume": "1603",
      "year": "1998"
    },
    {
      "DOI": "10.1186/s12885-020-07174-9",
      "author": "M Ang",
      "doi-asserted-by": "crossref",
      "first-page": "894",
      "journal-title": "BMC Cancer",
      "key": "227_CR17",
      "unstructured": "Ang M, Borg M, O’Callaghan ME, South Australian Prostate Cancer Clinical Outcomes C (2020) Survival outcomes in men with a positive family history of prostate cancer: a registry based study. BMC Cancer 201:894",
      "volume": "201",
      "year": "2020"
    },
    {
      "DOI": "10.1001/jama.1997.03550150055035",
      "author": "H Gronberg",
      "doi-asserted-by": "crossref",
      "first-page": "1251",
      "journal-title": "JAMA",
      "key": "227_CR18",
      "unstructured": "Gronberg H, Isaacs SD, Smith JR, Carpten JD, Bova GS, Freije D, Xu J et al (1997) Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus. JAMA 27815:1251–1255",
      "volume": "27815",
      "year": "1997"
    },
    {
      "DOI": "10.1097/00001648-199711000-00011",
      "author": "C Rodriguez",
      "doi-asserted-by": "crossref",
      "first-page": "653",
      "journal-title": "Epidemiology",
      "key": "227_CR19",
      "unstructured": "Rodriguez C, Calle EE, Miracle-McMahill HL, Tatham LM, Wingo PA, Thun MJ, Heath CW Jr (1997) Family history and risk of fatal prostate cancer. Epidemiology 86:653–657",
      "volume": "86",
      "year": "1997"
    },
    {
      "DOI": "10.1016/j.urology.2012.10.074",
      "author": "A Elshafei",
      "doi-asserted-by": "crossref",
      "first-page": "826",
      "journal-title": "Urology",
      "key": "227_CR20",
      "unstructured": "Elshafei A, Moussa AS, Hatem A, Ethan V, Panumatrassamee K, Hernandez AV, Jones JS (2013) Does positive family history of prostate cancer increase the risk of prostate cancer on initial prostate biopsy? Urology 814:826–830",
      "volume": "814",
      "year": "2013"
    },
    {
      "DOI": "10.1093/annonc/mdr056",
      "author": "A Brandt",
      "doi-asserted-by": "crossref",
      "first-page": "251",
      "journal-title": "Ann Oncol",
      "key": "227_CR21",
      "unstructured": "Brandt A, Sundquist J, Hemminki K (2012) Risk for incident and fatal prostate cancer in men with a family history of any incident and fatal cancer. Ann Oncol 231:251–256",
      "volume": "231",
      "year": "2012"
    },
    {
      "DOI": "10.1056/NEJMoa1603144",
      "author": "CC Pritchard",
      "doi-asserted-by": "crossref",
      "first-page": "443",
      "journal-title": "N Engl J Med",
      "key": "227_CR22",
      "unstructured": "Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A et al (2016) Inherited DNA-repair gene variants in men with metastatic prostate cancer. N Engl J Med 3755:443–453",
      "volume": "3755",
      "year": "2016"
    },
    {
      "DOI": "10.1056/NEJMoa1506859",
      "author": "J Mateo",
      "doi-asserted-by": "crossref",
      "first-page": "1697",
      "journal-title": "N Engl J Med",
      "key": "227_CR23",
      "unstructured": "Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Nava Rodrigues D et al (2015) DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med 37318:1697–1708",
      "volume": "37318",
      "year": "2015"
    },
    {
      "DOI": "10.1200/JCO.2019.37.15_suppl.5038",
      "author": "JM Mota",
      "doi-asserted-by": "crossref",
      "first-page": "5038",
      "issue": "15_suppl",
      "journal-title": "J Clin Oncol",
      "key": "227_CR24",
      "unstructured": "Mota JM, Barnett E, Nauseef J, Stopsack KH, Wibmer AG, Danila DC, Rathkopf DE et al (2019) Platinum-based chemotherapy in metastatic prostate cancer with alterations in DNA damage repair genes. J Clin Oncol 37(15_suppl):5038–5038",
      "volume": "37",
      "year": "2019"
    },
    {
      "DOI": "10.1016/j.eururo.2018.09.048",
      "author": "Z Zafeiriou",
      "doi-asserted-by": "crossref",
      "first-page": "184",
      "journal-title": "Eur Urol",
      "key": "227_CR25",
      "unstructured": "Zafeiriou Z, Bianchini D, Chandler R, Rescigno P, Yuan W, Carreira S, Barrero M et al (2019) Genomic analysis of three metastatic prostate cancer patients with exceptional responses to carboplatin indicating different types of DNA repair deficiency. Eur Urol 751:184–192",
      "volume": "751",
      "year": "2019"
    },
    {
      "DOI": "10.1001/jamaoncol.2018.6760",
      "author": "P Nicolosi",
      "doi-asserted-by": "crossref",
      "first-page": "523",
      "journal-title": "JAMA Oncol",
      "key": "227_CR26",
      "unstructured": "Nicolosi P, Ledet E, Yang S, Michalski S, Freschi B, O’Leary E, Esplin ED et al (2019) Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines. JAMA Oncol 54:523–528",
      "volume": "54",
      "year": "2019"
    },
    {
      "DOI": "10.1038/bjc.2014.30",
      "author": "D Leongamornlert",
      "doi-asserted-by": "crossref",
      "first-page": "1663",
      "journal-title": "Br J Cancer",
      "key": "227_CR27",
      "unstructured": "Leongamornlert D, Saunders E, Dadaev T, Tymrakiewicz M, Goh C, Jugurnauth-Little S, Kozarewa I et al (2014) Frequent germline deleterious variants in DNA repair genes in familial prostate cancer cases are associated with advanced disease. Br J Cancer 1106:1663–1672",
      "volume": "1106",
      "year": "2014"
    },
    {
      "DOI": "10.1038/bjc.2012.486",
      "author": "C Cybulski",
      "doi-asserted-by": "crossref",
      "first-page": "461",
      "journal-title": "Br J Cancer",
      "key": "227_CR28",
      "unstructured": "Cybulski C, Wokolorczyk D, Kluzniak W, Jakubowska A, Gorski B, Gronwald J, Huzarski T et al (2013) An inherited NBN variant is associated with poor prognosis prostate cancer. Br J Cancer 1082:461–468",
      "volume": "1082",
      "year": "2013"
    },
    {
      "DOI": "10.4143/crt.2018.532",
      "author": "B Rusak",
      "doi-asserted-by": "crossref",
      "first-page": "1180",
      "journal-title": "Cancer Res Treat",
      "key": "227_CR29",
      "unstructured": "Rusak B, Kluzniak W, Wokolorczykv D, Stempa K, Kashyap A, Gronwald J, Huzarski T et al (2019) Inherited NBN variants and prostate cancer risk and survival. Cancer Res Treat 513:1180–1187",
      "volume": "513",
      "year": "2019"
    },
    {
      "DOI": "10.1086/426403",
      "author": "C Cybulski",
      "doi-asserted-by": "crossref",
      "first-page": "1131",
      "journal-title": "Am J Hum Genet",
      "key": "227_CR30",
      "unstructured": "Cybulski C, Gorski B, Huzarski T, Masojc B, Mierzejewski M, Debniak T, Teodorczyk U et al (2004) CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 756:1131–1135",
      "volume": "756",
      "year": "2004"
    },
    {
      "DOI": "10.1038/sj.bjc.6601425",
      "author": "EH Seppala",
      "doi-asserted-by": "crossref",
      "first-page": "1966",
      "journal-title": "Br J Cancer",
      "key": "227_CR31",
      "unstructured": "Seppala EH, Ikonen T, Mononen N, Autio V, Rokman A, Matikainen MP, Tammela TL et al (2003) CHEK2 variants associate with hereditary prostate cancer. Br J Cancer 8910:1966–1970",
      "volume": "8910",
      "year": "2003"
    },
    {
      "DOI": "10.1155/2014/294575",
      "author": "V Hale",
      "doi-asserted-by": "crossref",
      "first-page": "294575",
      "journal-title": "Prostate Cancer",
      "key": "227_CR32",
      "unstructured": "Hale V, Weischer M, Park JY (2014) CHEK2 (*) 1100delC variant and risk of prostate cancer. Prostate Cancer 2014:294575",
      "volume": "2014",
      "year": "2014"
    },
    {
      "DOI": "10.1158/0008-5472.CAN-04-0341",
      "author": "C Cybulski",
      "doi-asserted-by": "crossref",
      "first-page": "2677",
      "journal-title": "Cancer Res",
      "key": "227_CR33",
      "unstructured": "Cybulski C, Huzarski T, Gorski B, Masojc B, Mierzejewski M, Debniak T, Gliniewicz B et al (2004) A novel founder CHEK2 variant is associated with increased prostate cancer risk. Cancer Res 648:2677–2679",
      "volume": "648",
      "year": "2004"
    },
    {
      "DOI": "10.1002/ijc.21022",
      "author": "N Bogdanova",
      "doi-asserted-by": "crossref",
      "first-page": "263",
      "journal-title": "Int J Cancer",
      "key": "227_CR34",
      "unstructured": "Bogdanova N, Enssen-Dubrowinskaja N, Feshchenko S, Lazjuk GI, Rogov YI, Dammann O, Bremer M et al (2005) Association of two variants in the CHEK2 gene with breast cancer. Int J Cancer 1162:263–266",
      "volume": "1162",
      "year": "2005"
    },
    {
      "DOI": "10.1016/j.eururo.2012.07.027",
      "author": "R Karlsson",
      "doi-asserted-by": "crossref",
      "first-page": "169",
      "journal-title": "Eur Urol",
      "key": "227_CR35",
      "unstructured": "Karlsson R, Aly M, Clements M, Zheng L, Adolfsson J, Xu J, Gronberg H et al (2014) A population-based assessment of germline HOXB13 G84E variant and prostate cancer risk. Eur Urol 651:169–176",
      "volume": "651",
      "year": "2014"
    },
    {
      "DOI": "10.1158/1055-9965.EPI-12-1000-T",
      "author": "VH Laitinen",
      "doi-asserted-by": "crossref",
      "first-page": "452",
      "journal-title": "Cancer Epidemiol Biomark Prev",
      "key": "227_CR36",
      "unstructured": "Laitinen VH, Wahlfors T, Saaristo L, Rantapero T, Pelttari LM, Kilpivaara O, Laasanen SL et al (2013) HOXB13 G84E variant in Finland: population-based analysis of prostate, breast, and colorectal cancer risk. Cancer Epidemiol Biomark Prev 223:452–460",
      "volume": "223",
      "year": "2013"
    },
    {
      "DOI": "10.1056/NEJMoa1110000",
      "author": "CM Ewing",
      "doi-asserted-by": "crossref",
      "first-page": "141",
      "journal-title": "N Engl J Med",
      "key": "227_CR37",
      "unstructured": "Ewing CM, Ray AM, Lange EM, Zuhlke KA, Robbins CM, Tembe WD, Wiley KE et al (2012) Germline variants in HOXB13 and prostate-cancer risk. N Engl J Med 3662:141–149",
      "volume": "3662",
      "year": "2012"
    },
    {
      "DOI": "10.1016/j.eururo.2018.11.015",
      "author": "T Nyberg",
      "doi-asserted-by": "crossref",
      "first-page": "834",
      "journal-title": "Eur Urol",
      "key": "227_CR38",
      "unstructured": "Nyberg T, Govindasami K, Leslie G, Dadaev T, Bancroft E, Ni Raghallaigh H, Brook MN et al (2019) Homeobox B13 G84E variant and prostate cancer risk. Eur Urol 755:834–845",
      "volume": "755",
      "year": "2019"
    },
    {
      "DOI": "10.1086/302320",
      "author": "P Hartge",
      "doi-asserted-by": "crossref",
      "first-page": "963",
      "journal-title": "Am J Hum Genet",
      "key": "227_CR39",
      "unstructured": "Hartge P, Struewing JP, Wacholder S, Brody LC, Tucker MA (1999) The prevalence of common BRCA1 and BRCA2 variants among Ashkenazi Jews. Am J Hum Genet 644:963–970",
      "volume": "644",
      "year": "1999"
    },
    {
      "author": "D Ford",
      "first-page": "692",
      "journal-title": "Breast Cancer Link Consort Lancet",
      "key": "227_CR40",
      "unstructured": "Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE (1994) Risks of cancer in BRCA1-variant carriers. Breast Cancer Link Consort Lancet 3438899:692–695",
      "volume": "3438899",
      "year": "1994"
    },
    {
      "DOI": "10.1093/jnci/91.15.1310",
      "author": "C Breast Cancer Linkage",
      "doi-asserted-by": "crossref",
      "first-page": "1310",
      "journal-title": "J Natl Cancer Inst",
      "key": "227_CR41",
      "unstructured": "Breast Cancer Linkage C (1999) Cancer risks in BRCA2 variant carriers. J Natl Cancer Inst 9115:1310–1316",
      "volume": "9115",
      "year": "1999"
    },
    {
      "DOI": "10.1016/j.eururo.2019.08.025",
      "author": "T Nyberg",
      "doi-asserted-by": "crossref",
      "first-page": "24",
      "journal-title": "Eur Urol",
      "key": "227_CR42",
      "unstructured": "Nyberg T, Frost D, Barrowdale D, Evans DG, Bancroft E, Adlard J, Ahmed M et al (2020) Prostate cancer risks for male BRCA1 and BRCA2 variant carriers: a prospective cohort study. Eur Urol 771:24–35",
      "volume": "771",
      "year": "2020"
    },
    {
      "DOI": "10.1158/1078-0432.CCR-08-1822",
      "author": "I Agalliu",
      "doi-asserted-by": "crossref",
      "first-page": "1112",
      "journal-title": "Clin Cancer Res",
      "key": "227_CR43",
      "unstructured": "Agalliu I, Gern R, Leanza S, Burk RD (2009) Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder variants. Clin Cancer Res 153:1112–1120",
      "volume": "153",
      "year": "2009"
    },
    {
      "DOI": "10.1007/s001090050162",
      "author": "S Sigurdsson",
      "doi-asserted-by": "crossref",
      "first-page": "758",
      "journal-title": "J Mol Med (Berl)",
      "key": "227_CR44",
      "unstructured": "Sigurdsson S, Thorlacius S, Tomasson J, Tryggvadottir L, Benediktsdottir K, Eyfjord JE, Jonsson E (1997) BRCA2 variant in Icelandic prostate cancer patients. J Mol Med (Berl) 7510:758–761",
      "volume": "7510",
      "year": "1997"
    },
    {
      "DOI": "10.1086/345310",
      "author": "SM Edwards",
      "doi-asserted-by": "crossref",
      "first-page": "1",
      "journal-title": "Am J Hum Genet",
      "key": "227_CR45",
      "unstructured": "Edwards SM, Kote-Jarai Z, Meitz J, Hamoudi R, Hope Q, Osin P, Jackson R et al (2003) Two percent of men with early-onset prostate cancer harbor germline variants in the BRCA2 gene. Am J Hum Genet 721:1–12",
      "volume": "721",
      "year": "2003"
    },
    {
      "DOI": "10.1038/sj.pcan.4500279",
      "author": "RA Eeles",
      "doi-asserted-by": "crossref",
      "first-page": "9",
      "journal-title": "Prostate Cancer Prostatic Dis",
      "key": "227_CR46",
      "unstructured": "Eeles RA (1999) Genetic predisposition to prostate cancer. Prostate Cancer Prostatic Dis 21:9–15",
      "volume": "21",
      "year": "1999"
    },
    {
      "DOI": "10.1158/0008-5472.CAN-19-1840",
      "author": "VL Patel",
      "doi-asserted-by": "crossref",
      "first-page": "624",
      "journal-title": "Cancer Res",
      "key": "227_CR47",
      "unstructured": "Patel VL, Busch EL, Friebel TM, Cronin A, Leslie G, McGuffog L, Adlard J et al (2020) Association of genomic domains in BRCA1 and BRCA2 with prostate cancer risk and aggressiveness. Cancer Res 803:624–638",
      "volume": "803",
      "year": "2020"
    },
    {
      "DOI": "10.1093/jnci/djm005",
      "author": "L Tryggvadottir",
      "doi-asserted-by": "crossref",
      "first-page": "929",
      "journal-title": "J Natl Cancer Inst",
      "key": "227_CR48",
      "unstructured": "Tryggvadottir L, Vidarsdottir L, Thorgeirsson T, Jonasson JG, Olafsdottir EJ, Olafsdottir GH, Rafnar T et al (2007) Prostate cancer progression and survival in BRCA2 variant carriers. J Natl Cancer Inst 9912:929–935",
      "volume": "9912",
      "year": "2007"
    },
    {
      "DOI": "10.1200/JCO.2012.43.1882",
      "author": "E Castro",
      "doi-asserted-by": "crossref",
      "first-page": "1748",
      "journal-title": "J Clin Oncol",
      "key": "227_CR49",
      "unstructured": "Castro E, Goh C, Olmos D, Saunders E, Leongamornlert D, Tymrakiewicz M, Mahmud N et al (2013) Germline BRCA variants are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol 3114:1748–1757",
      "volume": "3114",
      "year": "2013"
    },
    {
      "DOI": "10.1158/1078-0432.CCR-09-2871",
      "author": "DJ Gallagher",
      "doi-asserted-by": "crossref",
      "first-page": "2115",
      "journal-title": "Clin Cancer Res",
      "key": "227_CR50",
      "unstructured": "Gallagher DJ, Gaudet MM, Pal P, Kirchhoff T, Balistreri L, Vora K, Bhatia J et al (2010) Germline BRCA variants denote a clinicopathologic subset of prostate cancer. Clin Cancer Res 167:2115–2121",
      "volume": "167",
      "year": "2010"
    },
    {
      "DOI": "10.1016/j.eururo.2014.10.022",
      "author": "E Castro",
      "doi-asserted-by": "crossref",
      "first-page": "186",
      "journal-title": "Eur Urol",
      "key": "227_CR51",
      "unstructured": "Castro E, Goh C, Leongamornlert D, Saunders E, Tymrakiewicz M, Dadaev T, Govindasami K et al (2015) Effect of BRCA variants on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer. Eur Urol 682:186–193",
      "volume": "682",
      "year": "2015"
    },
    {
      "DOI": "10.1200/JCO.18.00358",
      "author": "E Castro",
      "doi-asserted-by": "crossref",
      "first-page": "490",
      "journal-title": "J Clin Oncol",
      "key": "227_CR52",
      "unstructured": "Castro E, Romero-Laorden N, Del Pozo A, Lozano R, Medina A, Puente J, Piulats JM et al (2019) PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair variants on the outcomes of patients with metastatic castration-resistant prostate cancer. J Clin Oncol 376:490–503",
      "volume": "376",
      "year": "2019"
    },
    {
      "DOI": "10.1016/j.eururo.2018.09.021",
      "author": "HB Carter",
      "doi-asserted-by": "crossref",
      "first-page": "743",
      "journal-title": "Eur Urol",
      "key": "227_CR53",
      "unstructured": "Carter HB, Helfand B, Mamawala M, Wu Y, Landis P, Yu H, Wiley K et al (2019) Germline variants in ATM and BRCA1/2 are associated with grade reclassification in men on active surveillance for prostate cancer. Eur Urol 755:743–749",
      "volume": "755",
      "year": "2019"
    },
    {
      "DOI": "10.1016/j.juro.2010.09.115",
      "author": "IF San Francisco",
      "doi-asserted-by": "crossref",
      "first-page": "471",
      "journal-title": "J Urol",
      "key": "227_CR54",
      "unstructured": "San Francisco IF, Werner L, Regan MM, Garnick MB, Bubley G, DeWolf WC (2011) Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance. J Urol 1852:471–476",
      "volume": "1852",
      "year": "2011"
    },
    {
      "DOI": "10.1038/ng.90",
      "author": "RA Eeles",
      "doi-asserted-by": "crossref",
      "first-page": "316",
      "journal-title": "Nat Genet",
      "key": "227_CR55",
      "unstructured": "Eeles RA, Kote-Jarai Z, Giles GG, Olama AA, Guy M, Jugurnauth SK, Mulholland S et al (2008) Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 403:316–321",
      "volume": "403",
      "year": "2008"
    },
    {
      "DOI": "10.1158/1055-9965.EPI-08-0317",
      "author": "Z Kote-Jarai",
      "doi-asserted-by": "crossref",
      "first-page": "2052",
      "journal-title": "Cancer Epidemiol Biomark Prev",
      "key": "227_CR56",
      "unstructured": "Kote-Jarai Z, Easton DF, Stanford JL, Ostrander EA, Schleutker J, Ingles SA, Schaid D et al (2008) Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium. Cancer Epidemiol Biomark Prev 178:2052–2061",
      "volume": "178",
      "year": "2008"
    },
    {
      "author": "RJ Macinnis",
      "first-page": "549",
      "journal-title": "Genet Epidemiol",
      "key": "227_CR57",
      "unstructured": "Macinnis RJ, Antoniou AC, Eeles RA, Severi G, Al Olama AA, McGuffog L, Kote-Jarai Z et al (2011) A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impact. Genet Epidemiol 356:549–556",
      "volume": "356",
      "year": "2011"
    },
    {
      "DOI": "10.1056/NEJMoa075819",
      "author": "SL Zheng",
      "doi-asserted-by": "crossref",
      "first-page": "910",
      "journal-title": "N Engl J Med",
      "key": "227_CR58",
      "unstructured": "Zheng SL, Sun J, Wiklund F, Smith S, Stattin P, Li G, Adami HO et al (2008) Cumulative association of five genetic variants with prostate cancer. N Engl J Med 3589:910–919",
      "volume": "3589",
      "year": "2008"
    },
    {
      "DOI": "10.1038/s41588-018-0142-8",
      "author": "FR Schumacher",
      "doi-asserted-by": "crossref",
      "first-page": "928",
      "journal-title": "Nat Genet",
      "key": "227_CR59",
      "unstructured": "Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T et al (2018) Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet 50:928–936",
      "volume": "50",
      "year": "2018"
    },
    {
      "DOI": "10.1200/JCO.2016.69.4935",
      "author": "J Lecarpentier",
      "doi-asserted-by": "crossref",
      "first-page": "2240",
      "journal-title": "J Clin Oncol",
      "key": "227_CR60",
      "unstructured": "Lecarpentier J, Silvestri V, Kuchenbaecker KB, Barrowdale D, Dennis J, McGuffog L, Soucy P et al (2017) Prediction of breast and prostate cancer risks in male BRCA1 and BRCA2 variant carriers using polygenic risk scores. J Clin Oncol 3520:2240–2250",
      "volume": "3520",
      "year": "2017"
    },
    {
      "author": "N Mottet",
      "key": "227_CR61",
      "unstructured": "Mottet N, van den Bergh RCN, Briers E, Cornford P, De Santis M, Fanti S, Gillessen S et al (2020) EAU - ESTRO - ESUR - SIOG guidelines on prostate cancer 2020, in European association of urology guidelines. European Association of Urology Guidelines Office, Arnhem",
      "volume-title": "EAU - ESTRO - ESUR - SIOG guidelines on prostate cancer 2020, in European association of urology guidelines",
      "year": "2020"
    },
    {
      "DOI": "10.7326/0003-4819-157-2-201207170-00459",
      "author": "VA Moyer",
      "doi-asserted-by": "crossref",
      "first-page": "120",
      "journal-title": "Ann Intern Med",
      "key": "227_CR62",
      "unstructured": "Moyer VA, Force USPST (2012) Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 1572:120–134",
      "volume": "1572",
      "year": "2012"
    },
    {
      "DOI": "10.1111/bju.13310",
      "author": "M Randazzo",
      "doi-asserted-by": "crossref",
      "first-page": "576",
      "journal-title": "BJU Int",
      "key": "227_CR63",
      "unstructured": "Randazzo M, Müller A, Carlsson S, Eberli D, Huber A, Grobholz R, Manka L et al (2016) A positive family history as a risk factor for prostate cancer in a population-based study with organised prostate-specific antigen screening: results of the Swiss European Randomised Study of Screening for Prostate Cancer (ERSPC, Aarau). BJU Int 1174:576–583",
      "volume": "1174",
      "year": "2016"
    },
    {
      "DOI": "10.1016/j.juro.2014.07.085",
      "author": "MA Liss",
      "doi-asserted-by": "crossref",
      "first-page": "75",
      "journal-title": "J Urol",
      "key": "227_CR64",
      "unstructured": "Liss MA, Chen H, Hemal S, Krane S, Kane CJ, Xu J, Kader AK (2015) Impact of family history on prostate cancer mortality in white men undergoing prostate specific antigen based screening. J Urol 1931:75–79",
      "volume": "1931",
      "year": "2015"
    },
    {
      "DOI": "10.1016/j.clgc.2019.05.015",
      "author": "O Abdel-Rahman",
      "doi-asserted-by": "crossref",
      "first-page": "e837",
      "journal-title": "Clin Genitourin Cancer",
      "key": "227_CR65",
      "unstructured": "Abdel-Rahman O (2019) Prostate cancer incidence and mortality in relationship to family history of prostate cancer; findings from the PLCO trial. Clin Genitourin Cancer 174:e837–e844",
      "volume": "174",
      "year": "2019"
    },
    {
      "DOI": "10.1056/NEJMoa030660",
      "author": "IM Thompson",
      "doi-asserted-by": "crossref",
      "first-page": "215",
      "journal-title": "N Engl J Med",
      "key": "227_CR66",
      "unstructured": "Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM et al (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 3493:215–224",
      "volume": "3493",
      "year": "2003"
    },
    {
      "DOI": "10.1093/jnci/djj131",
      "author": "IM Thompson",
      "doi-asserted-by": "crossref",
      "first-page": "529",
      "journal-title": "J Natl Cancer Inst",
      "key": "227_CR67",
      "unstructured": "Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, Feng Z et al (2006) Assessing prostate cancer risk: results from the prostate cancer prevention trial. J Natl Cancer Inst 988:529–534",
      "volume": "988",
      "year": "2006"
    },
    {
      "DOI": "10.1056/NEJMoa0908127",
      "author": "GL Andriole",
      "doi-asserted-by": "crossref",
      "first-page": "1192",
      "journal-title": "N Engl J Med",
      "key": "227_CR68",
      "unstructured": "Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA et al (2010) Effect of dutasteride on the risk of prostate cancer. N Engl J Med 36213:1192–1202",
      "volume": "36213",
      "year": "2010"
    },
    {
      "DOI": "10.1016/S1569-9056(10)60940-2",
      "author": "TLJ Tammela",
      "doi-asserted-by": "crossref",
      "first-page": "301",
      "journal-title": "Eur Urol Suppl",
      "key": "227_CR69",
      "unstructured": "Tammela TLJ, Andriole GL, Teloken C, Wilson TH, Fowler IL, Castro R (2010) 960 the influence of a positive family history on prostate cancer incidence and dutasteride efficacy in the reduce Study. Eur Urol Suppl 92:301",
      "volume": "92",
      "year": "2010"
    },
    {
      "DOI": "10.1002/pros.21002",
      "author": "J Xu",
      "doi-asserted-by": "crossref",
      "first-page": "1565",
      "journal-title": "Prostate",
      "key": "227_CR70",
      "unstructured": "Xu J, Sun J, Kader AK, Lindstrom S, Wiklund F, Hsu FC, Johansson JE et al (2009) Estimation of absolute risk for prostate cancer using genetic markers and family history. Prostate 6914:1565–1572",
      "volume": "6914",
      "year": "2009"
    },
    {
      "DOI": "10.1016/j.eururo.2012.05.006",
      "author": "AK Kader",
      "doi-asserted-by": "crossref",
      "first-page": "953",
      "journal-title": "Eur Urol",
      "key": "227_CR71",
      "unstructured": "Kader AK, Sun J, Reck BH, Newcombe PJ, Kim ST, Hsu FC, D’Agostino RB Jr et al (2012) Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial. Eur Urol 626:953–961",
      "volume": "626",
      "year": "2012"
    },
    {
      "DOI": "10.1001/jamanetworkopen.2019.18145",
      "author": "R Na",
      "doi-asserted-by": "crossref",
      "first-page": "e1918145",
      "journal-title": "JAMA Netw Open",
      "key": "227_CR72",
      "unstructured": "Na R, Labbate C, Yu H, Shi Z, Fantus RJ, Wang CH, Andriole GL et al (2019) Single-nucleotide polymorphism-based genetic risk score and patient age at prostate cancer diagnosis. JAMA Netw Open 212:e1918145",
      "volume": "212",
      "year": "2019"
    },
    {
      "DOI": "10.1371/journal.pmed.1002998",
      "author": "T Callender",
      "doi-asserted-by": "crossref",
      "first-page": "e1002998",
      "journal-title": "PLoS Med",
      "key": "227_CR73",
      "unstructured": "Callender T, Emberton M, Morris S, Eeles R, Kote-Jarai Z, Pharoah PDP, Pashayan N (2019) Polygenic risk-tailored screening for prostate cancer: a benefit-harm and cost-effectiveness modelling study. PLoS Med 1612:e1002998",
      "volume": "1612",
      "year": "2019"
    },
    {
      "DOI": "10.1038/gim.2014.192",
      "author": "N Pashayan",
      "doi-asserted-by": "crossref",
      "first-page": "789",
      "journal-title": "Genet Med",
      "key": "227_CR74",
      "unstructured": "Pashayan N, Duffy SW, Neal DE, Hamdy FC, Donovan JL, Martin RM, Harrington P et al (2015) Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis. Genet Med 1710:789–795",
      "volume": "1710",
      "year": "2015"
    },
    {
      "DOI": "10.1200/JCO.2017.74.1173",
      "author": "VN Giri",
      "doi-asserted-by": "crossref",
      "first-page": "414",
      "journal-title": "J Clin Oncol",
      "key": "227_CR75",
      "unstructured": "Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE et al (2018) Role of genetic testing for inherited prostate cancer risk: Philadelphia prostate cancer consensus conference 2017. J Clin Oncol 364:414–424",
      "volume": "364",
      "year": "2018"
    },
    {
      "DOI": "10.1200/JCO.20.00046",
      "author": "VN Giri",
      "doi-asserted-by": "crossref",
      "first-page": "2798",
      "journal-title": "J Clin Oncol",
      "key": "227_CR76",
      "unstructured": "Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, Dahut W et al (2020) Implementation of germline testing for prostate cancer: Philadelphia prostate cancer consensus conference 2019. J Clin Oncol 38:2798–2811",
      "volume": "38",
      "year": "2020"
    },
    {
      "DOI": "10.6004/jnccn.2020.0017",
      "author": "MB Daly",
      "doi-asserted-by": "crossref",
      "first-page": "380",
      "journal-title": "J Natl Compr Cancer Netw",
      "key": "227_CR77",
      "unstructured": "Daly MB, Pilarski R, Yurgelun MB, Berry MP, Buys SS, Dickson P, Domchek SM et al (2020) NCCN guidelines insights: genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 1.2020. J Natl Compr Cancer Netw 184:380–391",
      "volume": "184",
      "year": "2020"
    },
    {
      "key": "227_CR78",
      "unstructured": "NCCN (2020) NCCN clinical practice guidelines in oncology: prostate cancer. Version 3.2020. Nov 18, 2020. https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf"
    },
    {
      "key": "227_CR79",
      "unstructured": "NCCN (2020) NCCN clinical practice guidelines in oncology: prostate cancer early detection. Version 2.2020 August 24, 2020. https://www.nccn.org/professionals/physician_gls/pdf/prostate_detection.pdf"
    },
    {
      "DOI": "10.1016/j.annonc.2020.06.011",
      "author": "C Parker",
      "doi-asserted-by": "crossref",
      "first-page": "1119",
      "journal-title": "Ann Oncol",
      "key": "227_CR80",
      "unstructured": "Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G, Tombal B et al (2020) Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 31:1119–1134",
      "volume": "31",
      "year": "2020"
    },
    {
      "DOI": "10.1634/theoncologist.2015-0336",
      "author": "E Castro",
      "doi-asserted-by": "crossref",
      "first-page": "716",
      "journal-title": "Oncologist",
      "key": "227_CR81",
      "unstructured": "Castro E, Mikropoulos C, Bancroft EK, Dadaev T, Goh C, Taylor N, Saunders E et al (2016) The PROFILE feasibility study: targeted screening of men with a family history of prostate cancer. Oncologist 216:716–722",
      "volume": "216",
      "year": "2016"
    },
    {
      "DOI": "10.1111/j.1464-410X.2010.09648.x",
      "author": "AV Mitra",
      "doi-asserted-by": "crossref",
      "first-page": "28",
      "journal-title": "BJU Int",
      "key": "227_CR82",
      "unstructured": "Mitra AV, Bancroft EK, Barbachano Y, Page EC, Foster CS, Jameson C, Mitchell G et al (2011) Targeted prostate cancer screening in men with variants in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. BJU Int 1071:28–39",
      "volume": "1071",
      "year": "2011"
    },
    {
      "DOI": "10.1001/jamaoncol.2018.0271",
      "author": "R Mano",
      "doi-asserted-by": "crossref",
      "first-page": "872",
      "journal-title": "JAMA Oncol",
      "key": "227_CR83",
      "unstructured": "Mano R, Tamir S, Kedar I, Benjaminov O, Baniel J, Tabachnik T, Margel D (2018) Malignant abnormalities in male BRCA variant carriers: results from a prospectively screened cohort. JAMA Oncol 46:872–874",
      "volume": "46",
      "year": "2018"
    },
    {
      "DOI": "10.1016/S1569-9056(19)31309-0",
      "author": "S Golan",
      "doi-asserted-by": "crossref",
      "first-page": "e1809",
      "journal-title": "Eur Urol Suppl",
      "key": "227_CR84",
      "unstructured": "Golan S, Sela S, Frumer M, Kedar I, Ber Y, Kedar D, Margel D (2019) PT104—genetic testing for hereditary prostate cancer among men in Israel. Eur Urol Suppl 181:e1809",
      "volume": "181",
      "year": "2019"
    },
    {
      "DOI": "10.1097/JU.0000000000000137",
      "author": "S Das",
      "doi-asserted-by": "crossref",
      "first-page": "223",
      "journal-title": "J Urol",
      "key": "227_CR85",
      "unstructured": "Das S, Salami SS, Spratt DE, Kaffenberger SD, Jacobs MF, Morgan TM (2019) Bringing prostate cancer germline genetics into clinical practice. J Urol 2022:223–230",
      "volume": "2022",
      "year": "2019"
    },
    {
      "DOI": "10.1200/JCO.2018.36.15_suppl.TPS5098",
      "author": "HH Cheng",
      "doi-asserted-by": "publisher",
      "journal-title": "J Clin Oncol",
      "key": "227_CR86",
      "unstructured": "Cheng HH, Bowen D, Klemfuss N, Sievers CM, Kang SH, Zhou A, Pritchard C et al (2018) The GENTleMEN study: genetic testing for men with metastatic prostate cancer in Washington state and beyond. J Clin Oncol. https://doi.org/10.1200/JCO.2018.36.15_suppl.TPS5098",
      "year": "2018"
    },
    {
      "DOI": "10.1016/S1470-2045(15)00361-7",
      "author": "H Gronberg",
      "doi-asserted-by": "publisher",
      "journal-title": "Lancet Oncol",
      "key": "227_CR87",
      "unstructured": "Gronberg H (2015) Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study. Lancet Oncol. https://doi.org/10.1016/S1470-2045(15)00361-7",
      "year": "2015"
    },
    {
      "DOI": "10.1136/bmjopen-2018-027816",
      "author": "T Nordström",
      "doi-asserted-by": "crossref",
      "first-page": "e027816",
      "journal-title": "BMJ Open",
      "key": "227_CR88",
      "unstructured": "Nordström T, Jäderling F, Carlsson S, Aly M, Grönberg H, Eklund M (2019) Does a novel diagnostic pathway including blood-based risk prediction and MRI-targeted biopsies outperform prostate cancer screening using prostate-specific antigen and systematic prostate biopsies? - protocol of the randomised study STHLM3MRI. BMJ Open 96:e027816–e027816",
      "volume": "96",
      "year": "2019"
    },
    {
      "DOI": "10.1200/JCO.2020.38.15_suppl.1505",
      "author": "RA Eeles",
      "doi-asserted-by": "crossref",
      "first-page": "1505",
      "issue": "15_suppl",
      "journal-title": "J Clin Oncol",
      "key": "227_CR89",
      "unstructured": "Eeles RA, Raghallaigh HN, Group TBS (2020) BARCODE 1: A pilot study investigating the use of genetic profiling to identify men in the general population with the highest risk of prostate cancer to invite for targeted screening. J Clin Oncol 38(15_suppl):1505–1505",
      "volume": "38",
      "year": "2020"
    },
    {
      "DOI": "10.1016/S0140-6736(16)32401-1",
      "author": "HU Ahmed",
      "doi-asserted-by": "crossref",
      "first-page": "815",
      "journal-title": "Lancet",
      "key": "227_CR90",
      "unstructured": "Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, Collaco-Moraes Y et al (2017) Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 38910071:815–822",
      "volume": "38910071",
      "year": "2017"
    },
    {
      "author": "V Kasivisvanathan",
      "first-page": "589",
      "journal-title": "N Engl J Med",
      "key": "227_CR91",
      "unstructured": "Kasivisvanathan V, Emberton M, Moore CM (2018) MRI-targeted biopsy for prostate-cancer diagnosis. N Engl J Med 3796:589–590",
      "volume": "3796",
      "year": "2018"
    }
  ],
  "reference-count": 91,
  "references-count": 91,
  "resource": {
    "primary": {
      "URL": "https://link.springer.com/10.1007/s10689-021-00227-3"
    }
  },
  "score": 0,
  "short-container-title": [
    "Familial Cancer"
  ],
  "source": "Crossref",
  "title": [
    "Genetic predisposition to prostate cancer: an update"
  ],
  "type": "journal-article",
  "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy",
  "volume": "21"
}